Cited by 303Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.

Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons

Le, Michael H., Le, David M., Baez, Thomas C., Wu, Yuankai, Ito, Takanori, Lee, Eunice Y., Lee, KeeSeok, Stave, Christopher D., Henry, Linda, Barnett, Scott D., Cheung, Ramsey, Nguyen, Mindie H.·2023·Journal of Hepatology

DOI 10.1016/j.jhep.2023.03.040

Open this paper in CoChat — free account

Abstract

Background & aims The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. We aimed to estimate the pooled global NAFLD incidence.Methods We performed a systematic review and meta-analysis of cohort studies of adults without NAFLD at baseline to evaluate the global incidence of ultrasound-diagnosed NAFLD.Results A total of 63 eligible studies (1,201,807 persons) were analyzed. Studies were from Mainland China/Hong Kong (n = 26), South Korea (n = 22), Japan (n = 14), other (n = 2, Sri Lanka, Israel); 63.8% were clinical center studies; median study year 2000 to 2016; 87% were good quality. Among the 1,201,807 persons at risk, 242,568 persons developed NAFLD, with an incidence rate of 4,612.8 (95% CI 3,931.5-5,294.2) per 100,000 person-years and no statistically significant differences by study sample size (p = 0.90) or study setting (p = 0.055). Males had higher incidence vs. females (5,943.8 vs. 3,671.7, p = 0.0013). Both the obese (vs. non-obese) and the overweight/obese groups (vs. normal weight) were about threefold more likely to develop NAFLD (8,669.6 vs. 2,963.9 and 8,416.6 vs. 3,358.2, respectively) (both p <0.0001). Smokers had higher incidence than non-smokers (8,043.2 vs. 4,689.7, p = 0.046). By meta-regression, adjusting for study year, study setting, and study location, study period of 2010 or after and study setting were associated with increased incidence (p = 0.010 and p = 0.055, respectively). By country, China had a higher NAFLD incidence compared to non-China regions (p = 0.012) and Japan a lower incidence compared to non-Japan regions (p = 0.005).Conclusions NAFLD incidence is increasing with a current estimate of 4,613 new cases per 100,000 person-years. Males and overweight/obese individuals had significantly higher incidence rates compared to females and those of normal weight. Public health interventions for prevention of NAFLD are needed with a special emphasis on males, overweight/obese individuals, and higher risk regions.Impact and implications Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of people worldwide and appears to be increasing, but data to estimate the incidence rate are limited. In this meta-analytic study of over 1.2 million people, we estimated an incidence rate of NAFLD of 46.13 per 1,000 person-years with significant differences by sex, BMI, geography, and time-period. As treatment options for NAFLD remain limited, prevention of NAFLD should remain the focus of public health strategies. Studies such as these can help policy makers in determining which and whether their interventions are impactful.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2023.03.040

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Untitled work
(2014) · Medical Entomology and Zoology · Cited by 17,633
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citation
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method
IntHout, J., Ioannidis, J. P., & Borm, G. F. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-25 · Cited by 2,419
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925

Flagged first, then by citations

Show all 51 references

3 of the 51 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 302

Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites
Li, P., Wu, Q., Zhou, Y., Hu, X., Tang, Y., Wang, Y.-Y., Fan, W., Shan, Y., Yu, K., Wang, J., et al. (2025) · Nano Research · doi:10.26599/nr.2025.94907986 · Cited by 9
Transcriptomics reveal a molecular signature in the progression of nonalcoholic steatohepatitis and identifies PAI‑1 and MMP‑9 as biomarkers in in vivo and in vitro studies
Zhao, Y., Yakufu, M., Ma, C., Wang, B., Yang, J., & Hu, J. (2023) · Molecular Medicine Reports · doi:10.3892/mmr.2023.13138 · Cited by 12
“Consequently, the identification of patients with NASH at an elevated risk of progressing to end stage liver disease is imperative for effective risk assessment and management (10,11).”
Sex-Related Differences in Cardiovascular Risk in Adolescents with Overweight or Obesity
Bonito, P. D., Sessa, A. D., Licenziati, M. R., Corica, D., Wasniewska, M. G., del Giudice, E. M., Morandi, A., Maffeis, C., Faienza, M. F., Mozzillo, E., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504141 · Cited by 9
“In addition, diseases associated to high cardiometabolic risk, such as type 2 diabetes [6] and FLD are more prevalent in males [7].”
Background
Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again
Li, L., Wang, Z., & Jiang, Y. D. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.030 · Cited by 9
Quantification of collagen fiber properties in alcoholic liver fibrosis using polarization-resolved second harmonic generation microscopy
Matsuzaki, S., Hase, E., Takanari, H., Hayashi, Y., Hayashi, Y., Oshikata, H., Minamikawa, T., Kimura, S., Ichimura-Shimizu, M., Yasui, T., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48887-8 · Cited by 8
Association between menopause, body composition, and nonalcoholic fatty liver disease: A prospective cohort in northern China
Yang, C., Chen, S., Feng, B., Lu, Y., Wang, Y., Liao, W., Wu, S., & Wang, L. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108148 · Cited by 8
Non-Alcoholic Fatty Liver Disease, Awareness of a Diagnostic Challenge—A Clinician’s Perspective
Mărginean, C. M., Pîrșcoveanu, D. F. V., Cazacu, S. M., Popescu, M. S., Mărginean, I. C., Iacob, G. A., & Popescu, M. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15040071 · Cited by 10
Macrophages Atp6v0d2 regulates XBP1-mediated cholesterol metabolism to suppress metabolic dysfunction-associated steatohepatitis progression
Wang, Z., Chen, X., Li, J., Chen, M., Zhu, H., Li, X., Yu, W., Xia, N. L., Zhang, Y., Sun, L., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115088 · Cited by 9
Serum Tsukushi Level Is Associated With the Severity of Liver Fibrosis Independent of Type 2 Diabetes
Lam, S., Lee, C., Fong, C. H.-Y., Wong, Y., Shiu, S. W. M., Mak, L., Yuen, M., Lam, K. S. L., & Tan, K. C. B. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad650 · Cited by 8
The independent and joint associations of vitamin B12 and methylmalonic acid on the risk of mortality in individuals with metabolic dysfunction-associated steatotic liver disease
Wang, P., Yu, J., Zhao, Y., Simayi, R., & Shi, D. (2024) · European Journal of Nutrition · doi:10.1007/s00394-024-03448-1 · Cited by 8
The trend in incidence of non-alcoholic fatty liver disease and its impact on cirrhosis and liver cancer: An analysis from Global Burden of Disease 2021
Gu, Y., Guo, C., Liu, Z., Han, X., Han, X., Zhang, X., Zhao, S., Wang, H., & Zhang, T. (2025) · Public Health · doi:10.1016/j.puhe.2025.02.028 · Cited by 11
Longitudinal association of peripheral blood DNA methylation with liver fat content: distinguishing between predictors and biomarkers
Zeng, H.-L., Li, W., Xia, M.-F., Ge, J., Ma, H., Chen, L.-Y., Pan, B.-S., Lin, H., Wang, S., & Gao, X. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02304-9 · Cited by 9
“The incidence rate of MASLD was reported to be highest in Mainland China [2].”
Background
The impact of chiglitazar, a pan-PPAR agonist, on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: a real-world study
Tan, Y., Qu, W., Zhao, J., Ma, Y., Zhang, Q., Gao, H., Zhen, Q., Wang, Y., Peng, Y., Liu, F., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101680 · Cited by 7
NAFLD incidence is increasing
Kotsiliti, E. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00787-y · Cited by 7
Expanding Pharmacists’ Role in the Management of Non-Alcoholic Fatty Liver Disease
Syed‐Abdul, M. M. (2023) · Pharmacy · doi:10.3390/pharmacy11050151 · Cited by 7
“The incidence rate is higher in males compared to females and in overweight/obese individuals compared to those with normal weight [8,9].”
Background
Prevalence, risk factors, quality of life, and awareness of MASLD among Egyptian university students: a cross-sectional study
El‐Kassas, M., Romeih, M. A. E.-H., Fangary, A., Abouelyazeed, A., Abdelfattah, I., Alerian, A., Ekbal, A., Elshaikh, Y. A., Abbas, S., Tahoon, M. A. H., et al. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00431-1 · Cited by 7
TRIB3 at the nexus of metabolic disorders: In-depth analysis of biochemical mechanisms and concepts for drug discovery
Peng, J., & Wang, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117108 · Cited by 6
Identifying metabolic dysfunction-associated steatotic liver disease in patients with hypertension and pre-hypertension: An interpretable machine learning approach
Chen, C., Zhang, W., Yan, G., & Tang, C. (2024) · Digital Health · doi:10.1177/20552076241233135 · Cited by 6
Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice
Liu, L., Sun, W., Tang, X., Zhen, D., Guan, C., Fu, S., & Liu, J. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112337 · Cited by 6
Celiac Disease and Liver Damage: The Gut–Liver Axis Strikes Back (Again)? A Retrospective Analysis in the Light of a Literature Review
Seidita, A., Latteri, F., Pistone, M., Giuliano, A., Bertoncello, L., Cavallo, G., Chiavetta, M., Faraci, F., Nigro, A., Termini, A., et al. (2024) · Nutrients · doi:10.3390/nu17010085 · Cited by 6
Trimester‐Specific Impacts of Steatotic Liver Disease on Adverse Pregnancy Outcomes: A Retrospective Cohort Study
Yang, L., Yang, S., Wang, Y., Hebestreit, A., Wang, M., Yang, Y., Wu, Y., Long, Y., & Wang, H. (2025) · Liver International · doi:10.1111/liv.70471 · Cited by 5
“With the global obesity pandemic, the incidence of MASLD in China has become the highest [6], resulting in a significant disease burden [7].”
Metabolic dysfunction associated steatotic liver disease: mechanisms, diagnosis, and management in adults
Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 9
Unveiling the hidden pathologies: preoperative endoscopic findings in patients with obesity undergoing bariatric surgery
Tian, P., Fu, J. H., Liu, Y., Li, M., Liu, J., Liu, J., Zhang, Z., & Zhang, P. (2024) · BMC Surgery · doi:10.1186/s12893-024-02502-3 · Cited by 5
Rheumatoid factor levels indicate cryoglobulinemia severity in hepatitis B e antigen-negative hepatitis B virus carriers: a 7-year prospective cohort study
Wu, J., Chen, W.-T., Huang, C., Chen, Y., Hsu, C., Chien, R., & Chang, M. (2024) · Hepatology International · doi:10.1007/s12072-024-10761-8 · Cited by 5
“The lower BMIs and lower proportion of patients with fatty liver among patients with cryoglobulinemia might be due to female dominance, given that females tend to have lower BMIs and a lower proportion of fatty liver than males do [33].”
Effects of zingerone supplementation on ovarian steroidogenesis and folliculogenesis in mouse
Dutta, A., Gurusubramanian, G., & Roy, V. K. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110043 · Cited by 5
Non-alcoholic fatty liver disease and gestational diabetes mellitus: a bidirectional two-sample mendelian randomization study
Zhou, B., Xia, J.-L., Jiang, X., Ding, Y., & She, Q. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01569-6 · Cited by 5
“A recent meta-analysis involving over 1.2 million people showed that the incidence rate of NAFLD was 46.13 per 1000 person years, with considerable disparities in gender, body mass index (BMI), geography and time-period [3].”
BackgroundInfluential
Serum uric acid and mortality in metabolic dysfunction-associated steatotic liver disease: Subgroup differences
Chen, W., Deng, Y., Li, M., Li, J., Cao, Y., & Xie, W. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.09.015 · Cited by 5
Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study
Lai, R., Barnett, S. D., Zhang, X., Kam, L. Y., Cheung, R. C., Xie, Q., & Nguyen, M. H. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004479 · Cited by 5
Renin-independent aldosteronism and metabolic dysfunction-associated steatotic liver disease and cirrhosis: A genetic association study
Zeng, Q., Luo, X., Chen, X., Luo, W., Li, R., Yang, S., Yang, J., Shu, X., Li, Q., Hu, J., et al. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.12.011 · Cited by 5
Muscle Strength and Cardiovascular Health in MASLD: A Prospective Study
Kumbaroğlu, F. B., Balaban, Y. H., & Düger, T. (2025) · Medicina · doi:10.3390/medicina61020247 · Cited by 5
“These factors, in conjunction with cardiovascular risk factors, facilitate the progression of liver pathology [8,9].”
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis
Ko, D., Kim, D. H., Danpanichkul, P., Nakano, M., Rattananukrom, C., Wijarnpreecha, K., Ng, C. H., & Muthiah, M. D. (2025) · Gastroenterology report · doi:10.1093/gastro/goaf037 · Cited by 5
Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in ratsPreprint
Yang, H., Zhang, C., Kim, W., Shi, M., Kılıçlıoğlu, M., Bayram, C., Bolat, İ., Tozlu, Ö. Ö., Baba, C., Yuksel, N., et al. (2024) · eLife · doi:10.7554/elife.98427 · Cited by 5
Association between cumulative uric acid exposure and metabolic dysfunction-associated fatty liver disease
Li, Y., Ji, H. L., Tian, F., Ge, X., Cao, L., & Ma, X. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04038-z · Cited by 4
“This is consistent with the known reports that HRs of MAFLD in smokers is significantly higher than that in non-smokers [35].”
The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Pieralice, S., Amendolara, R., Berna, V., Manganaro, G., Zurru, A., D’Onofrio, L., Risi, R., Alfonsi, M., Maddaloni, E., & Buzzetti, R. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s528569 · Cited by 7
NAFLD in adolescents aged 10–19: Global Burden of Disease analysis from 1990 to 2021
Luo, Y., Wang, L., Yang, X., & Zhu, L. (2025) · Medicine · doi:10.1097/md.0000000000045051 · Cited by 4
“…trend in men (EAPC 0.93 [95% CI: 0.84–1.01]) compared to women (EAPC 0.79 [95% CI: 0.75–0.85]), consistent with a large meta-analysis by Le et al, [17] which reported significantly higher incidence in males (5943.8 per 100,000 person-years) than in females (3671.7 per 100,000 person-years).”
Influential
Hydroxytyrosol Improves Metabolic Dysfunction-Associated Fatty Liver Disease Dependent on the Modulation of Gut Microbiota
Xiao, Y., Zhang, X., Shao, B., Wu, Z., Li, X., Yi, D., Li, T., Yang, T., Zhu, J.-X., Huang, T., et al. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c07003 · Cited by 4
Precision Modulation of Gut Microbiome via Metagenomic-driven Dietary and Probiotic Interventions for Non-alcoholic Fatty Liver Disease Management in Obese Saudis
Alherfi, M. M., Khazna, M. S., Al-Dakhil, A., Alghamdi, S., Altahhan, M. E., Alalwani, J. F., Asiri, F. S. H., Alkhars, A. H. A., & Mohaini, M. A. (2025) · Journal of Advanced Trends in Medical Research · doi:10.4103/atmr.atmr_101_25 · Cited by 4
Glycine attenuates high fructose-induced liver injury in adolescent mice by modulating lipid metabolism and gut microbiota
Ge, Y., Deng, S., Zhang, X., Liu, H., Chen, Y., Liu, Y., Liu, S., Fu, H., Yang, Y., & Wu, Z. (2025) · Food & Function · doi:10.1039/d4fo01605j · Cited by 4
Global, regional, and national burden of NAFLD in adults aged 20–49 years (1990–2021): a comprehensive analysis of trends, decomposition, and health inequality
Zhong, Z., Xu, M., Luo, X., & Tan, J. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04497-4 · Cited by 6
“…the global prevalence of NAFLD has been rising steadily, driven by increasing rates of obesity and associated comorbidities, such as T2DM and hypertension, especially in low-and middle-income countries where dietary patterns are shifting rapidly due to urbanization and globalization [12–14].”
Underuse of statins in MASLD despite population-based associations with lower liver stiffness
Pustjens, J., van Kleef, L. A., Pavlović, J., Lahousse, L., Holleboom, A. G., Janssen, H. L. A., Ayada, I., Kavousi, M., Chaker, L., van Lennep, J. E. R., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101764 · Cited by 4
PGC-1α protects against MASH via Tim23-dependent inhibition of DRP1-mediated ferroptosis
Zhao, Y., Zhang, L.-Z., Li, B.-R., Liu, M.-H., Zhang, Y.-T., Li, T., Ning, S.-B., & Zhang, X.-Y. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08493-8 · Cited by 4
“…( α -SMA), collagen I, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), cytochrome c oxidase subunit 4 (COXIV) and cleaved caspase-3 (Cell Signaling Technology, Beverly, USA); PGC-1 α , ACSL4, tumor necrosis factor (TNF) α , Hepatocyte nuclear factor 4-alpha (HNF-4 α ), Desmin and…”
Italian style coffee consumption and metabolically dysfunctional-associated steatotic liver disease (MASLD): a cohort population study in Southern Italy
Siani, M., Bonfiglio, C., Bonfrate, L., Donghia, R., & Pastore, M. N. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1797230 · Cited by 4
“MASLD is currently the most prevalent chronic liver disease globally, with a prevalence of over 30% (5) and incidence rates continuing to rise, particularly in males and overweight/obese individuals (6).”
Metabolic Dysfunction-Associated Steatotic Liver Disease
Paik, J. M., Henry, L. L., AlNaamani, K. M., Nader, A., Stepanova, M., Lee, M., Yu, M., & Younossi, Z. M. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.001 · Cited by 4
The kidney in the middle: Kidney Disease: Improving Global Outcomes (KDIGO) guidelines address multiple key components of cardiovascular-kidney-metabolic syndrome
Levin, A., Bansal, N., de Boer, I. H., Grams, M. E., Jadoul, M., ter Maaten, J. M., Mustafa, R. A., Rossing, P. R., Cheung, M., King, J. M., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.03.031 · Cited by 4
Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options
Ren, R., Liang, X., & Wei, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00486-5 · Cited by 5
“This alarming trajectory is particularly pronounced in China, which reports among the highest incidence rates globally, driven by dietary shifts toward ultra-processed foods, increasingly sedentary lifestyles, and an aging population [15–17].”
Nutritional Interventions Targeting the Gut Microbiome in MASLD: From Prebiotics and Probiotics to Postbiotics and Fecal Microbiota Transplantation
Acierno, C., Caturano, A., Barletta, F., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Nevola, R. (2026) · Nutrients · doi:10.3390/nu18111765 · Cited by 4
“Its global prevalence, commonly estimated at approximately one-third of the adult population [2,3], gives the condition major public health relevance well beyond hepatol-ogy, particularly because disease burden is driven not only by progressive steatohepatitis and fibrosis in a clinically important…”
Clinical model to predict the risk of nonalcoholic fatty liver disease: A secondary analysis of data from a cross-sectional study
Yang, B., & Zhong, X. (2024) · Medicine · doi:10.1097/md.0000000000039437 · Cited by 4
“[5] NAFLD may progress to cirrhosis and increase the likelihood of hepatocellular cancer, and gut microbiota dysbiosis plays a critical role in this process by disrupting the gut–liver axis and immune system function.”
Background
Addressing the essentials of the recent guidelines for managing patients with metabolic dysfunction-associated steatotic liver disease
Karagiannakis, D. S., Stefanaki, K., Paschou, S. Α., Papatheodoridi, Μ., Tsiodras, S., & Παπάνας, Ν. (2024) · HORMONES · doi:10.1007/s42000-024-00625-z · Cited by 4
Cardiometabolic risk factors, metabolic profile and body composition in young adults with non-alcoholic fatty liver disease
Pankova, E. D., Чулков, В. С., Сергеевич, Ч. В., Minina, E. E., Ektova, N. A., Dmitrieva, A., & Гасанов, М. З. (2025) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2025-4094 · Cited by 4
Predictive effect and clinical diagnosis significance of exosome-related genes for nonalcoholic fatty liver disease-related hepatocellular carcinoma
Ding, X., Li, L., Feng, K., Zhang, J., Sun, B., Chu, X., Zhang, Q., & Zhuang, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-07286-x · Cited by 4
Impacts of Ramadan Fasting on Metabolic and Hepatic Endpoints in Individuals With Metabolic Dysfunction‐Associated Fatty Liver Disease: A Systematic Review and Meta‐Analysis
Kamrul-Hasan, A. B. M., Ashraf, H., Nagendra, L., Dutta, D., Shahriar, M., Islam, S., & Pappachan, J. M. (2025) · JGH Open · doi:10.1002/jgh3.70264 · Cited by 4
“This condition is more common among men and those who are overweight or obese [3].”
From NAFLD to MASLD: Meta-analysis and systematic review of NAFLD patients in Turkiye in terms of metabolic profile and MASLD potential
Akdaş, S., & Yazıhan, N. (2024) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0042 · Cited by 4
“[5] A single-center study investigating Turkiye’s NAFLD profile revealed that 90.4% of NAFLD patients had biopsy-proven NASH, and simple steatosis was rare (9.6%).”
BackgroundInfluential
Chronic pharmacologic manipulation of dopamine transmission ameliorates metabolic disturbance in Trappc9-linked brain developmental syndrome
Li, Y., Usman, M., Sapp, E., Ke, Y., Wang, Z., Boudi, A., DiFiglia, M., & Li, X. (2024) · JCI Insight · doi:10.1172/jci.insight.181339 · Cited by 4
Impact of peripheral thyroid hormone balance on liver fat: insights from the NutriAct trial
Sommer, M., Nguyen, T.-H., Pletsch‐Borba, L., Wernicke, C., Tacke, F., Schwerdtle, T., Pellowski, D., Machann, J., Spranger, J., Wirth, E. K., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae093 · Cited by 6
Ramadan Fasting and Complications of Metabolic Dysfunction-Associated Steatotic Liver Disease: Impacts on Liver Cirrhosis and Heart Failure
Ahmed, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061841 · Cited by 5
“The global prevalence of MASLD is approximately 25% [9].”
Steatotic liver disease: Know your enemies
Mak, L. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0078 · Cited by 4
Alterations in hepatic amino acid metabolism related to MASLD in individuals with obesity
Pérez-Díaz, A. J., Ros‐Madrid, I., Martínez‐Sánchez, M. A., Rico‐Chazarra, S., Oliva‐Bolarín, A., Román, A. B., Fernández-Ruiz, V. E., Martínez, C. M., Yuste, J. E., Ferrer‐Gómez, M., et al. (2025) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-025-01086-7 · Cited by 3
Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues
Yu, H., Wu, J., Li, M., Hu, C., Ren, Y., Jiang, H., Huang, Y., Lei, Y., Chen, J., Wu, B., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70099 · Cited by 3
“This prevalence notably varies across clinical settings, ethnic populations, and geographical regions [2, 3].”
A systematic review and meta-analysis of the association between cardiovascular health determined by life's essential 8 and risk of mortality and major non-communicable diseases
Li, G., Zhang, Y., Wu, Q., Shi, B., & Chen, D. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1612056 · Cited by 3
ATG9A-PLA2G6 axis reprograms phospholipid metabolism to drive metabolic liver disease and hepatocellular carcinoma
Zhu, Q., Gu, Y., Gao, Y., Zhao, X., & Zhang, L. (2025) · Autophagy · doi:10.1080/15548627.2025.2601035 · Cited by 3
Mitochondria-targeted antioxidant AntiOxBEN2 prevents metabolic dysfunction-associated steatotic liver disease (MASLD) by enhancing fatty acid oxidation and mitochondrial bioenergetics
Amorim, R., Magalhães, C. C., Duarte, A. I., de Lemos, A. C., Carvalho, A. P., Pereira, S. P., Grilo, L. F., Mena, D., Gerardo, H., Veloso, C. D., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119022 · Cited by 3
Nonlinear climate–Liver gradients: Non-optimal temperature and variability increase risk of metabolic dysfunction-associated steatotic liver disease
Wang, Y., Gao, X., Wang, Q., Li, Y., Li, Q., Xing, Y., Yang, S., Yang, Y., Wang, M., Wu, Y., et al. (2026) · Global Transitions · doi:10.1016/j.glt.2026.02.003 · Cited by 3
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection
Bhatti, T. K., & Lim, J. K. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i9.115544 · Cited by 3
Development and Validation of a Risk Prediction Model for NAFLD: A Study Based on a Physical Examination Population
Yang, C.-M., Du, T., Zhao, Y., Qian, Y., Tang, J., Li, X., & Ma, L. (2024) · Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy · doi:10.2147/dmso.s438652 · Cited by 2
Association between hepatocyte TM4SF5 expression and gut microbiome dysbiosis during non-alcoholic fatty liver disease development
Pinanga, Y. D., Pyo, K., Shin, E., Lee, H., Lee, E. H., Kim, W., Kim, S., Kim, J. E., Kim, S., & Lee, S. E. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123164 · Cited by 3
Garcinol enriched fraction of Garcinia morella (Gaertn.) Desr. fruit rind improves gut health and reduces the risk of nonalcoholic fatty liver disease by regulating PCK1/ACC/SREBP1/FASn pathway in a mouse model
Basumatary, D., Das, S., Devi, M. B., Devi, G. S., Sarma, P., Mukherjee, A. K., Khan, M. R., & Borah, J. C. (2024) · Food Research International · doi:10.1016/j.foodres.2024.115285 · Cited by 4
The causal impact of body mass index on metabolic biomarkers and nonalcoholic fatty liver disease risk
Wang, B., Yang, Y., Yin, Z., & Yang, W. (2025) · Scientific Reports · doi:10.1038/s41598-024-84165-x · Cited by 5
A novel EndMT inhibitor, xanthotoxin, attenuates non-alcoholic fatty liver disease by acting as TGFβR2 antagonist
Zhao, X., Xia, F., Dong, Z., Huang, W., Kong, X., Cui, Z., Yan, M., Gao, H., Rong, R., Wang, M., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156823 · Cited by 3
Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 3
“%) and affects up to 70% of T2DM patients, adding to their health burden [3–5].”
Effects of vitamin D supplementation combined with exercise on glucolipid metabolism in adults: A meta-analysis
Feng, Y., Zhou, W., & Niu, Y. (2025) · iScience · doi:10.1016/j.isci.2025.113243 · Cited by 4
Survey of physicians' knowledge about pediatric nonalcoholic fatty liver disease in China
Gao, X. Y., Yang, Y. F., Li, L., Xing, Y. F., Wang, Y. X., Li, X. Y., Yang, S., Wang, M. Y., Fan, J., & Wang, H. (2024) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13297 · Cited by 3
The association between familial Mediterranean fever and incident cirrhosis: A population-based matched cohort study
Carmiel-Haggai, M., Daood, R., Fassan, F., Jeries, H., Dror-Zur, D., Omar, M., Watad, ‬., Patalon, T., & Naffaa, M. E. (2025) · Joint Bone Spine · doi:10.1016/j.jbspin.2025.105917 · Cited by 3
Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study.
Lee, C.-H., Kang, M.-G., Oh, S., Gwak, I. S., Shen, C., Oh, H., Park, Y. R., Kim, J. S., & Park, J. H. (2025) · Clinics And Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102612 · Cited by 3
Identification of CDKN1A as a potential key risk factor in MASLD progression
Deng, L., Deng, J., Luo, L., Yang, H., Sun, M., Yucheng, G., Liu, Q., Ngowi, E. E., Zhou, Y., Zhang, R., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202402942r · Cited by 2
“2,3 Excessive accumulation of fatty acids in the liver, or disruptions in the metabolic pathways of fatty acids, leads to the production of lipotoxic substances, which cause cell damage, inflammation, programmed cell death, and fibrotic remodeling.”
Reference ranges for liver function tests in pregnancy controlling for maternal characteristics
Judah, H., Rigby, R. A., Stasinopoulos, M. D., Pateras, K., Rahim, M. N., Heneghan, M. A., Nicolaides, K. H., & Kametas, N. A. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2025.06.056 · Cited by 2
The Burden of Nonmalignant Metabolic Dysfunction‐Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis From 1990 to 2021
Ge, Q., Lin, Y., Wang, M., Zhu, J., Zhang, Q., Wang, J., Yang, Y., Zhangdi, H., Guo, Y., Wang, S., et al. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70627 · Cited by 2
Analysis of Health-Related Quality of Life and Its Influencing Factors Among Patients with Non-Alcoholic Fatty Liver Disease in Hangzhou, China: A Cross-Sectional Study
Fei, H., Lv, K., Xu, J., Hao, H., Quan, Y., Shi, J., & Zhang, W. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251363914 · Cited by 2
Lactobacillus gasseri TF08-1 ameliorates high-fat diet induced nonalcoholic fatty liver disease and regulates gut microbiota in mice
Xu, Q., He, N., Tian, Y., Wu, Z., Wang, H., Liu, B., Yang, Z., Zhang, H., Luo, Q., Zhong, Y., et al. (2025) · Journal of Applied Microbiology · doi:10.1093/jambio/lxaf271 · Cited by 2
Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?
Elmustafa, F., Tyagi, M., Kaur, H., Blaney, H. L., Xie, C., Jalil, S., & Singal, A. K. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00712-8 · Cited by 3
Association of Fasting C-Peptide to High Density Lipoprotein Cholesterol Ratio with Non-Alcoholic Fatty Liver Disease in Chinese Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study
Liang, Q., Hu, H., Chen, X., Yang, S., Zhang, Y., Wu, Y., Wang, X., & Chen, H. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s556539 · Cited by 2
“4,8 The poor prognosis of NAFLD is primarily associated with cardiovascular diseases and non-liver malignancies.”
Chronotype, serum metabolome, and nonalcoholic fatty liver disease in middle-aged and older adults: Association and potential mediation analyses
Hu, M.-J., Dong, X., Wang, X., Yao, B., Fu, Y., Su, D., Li, L., Zhang, Y., & Chu, X.-M. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112998 · Cited by 2
The association between organophosphate pesticide residue exposure and non-alcoholic fatty liver disease: A systematic review
Mohamadi, B., Ostadan, M. T., Shokri, S., Bakhtiyari, A., Rasooli, R., Sadighara, P., & Bekheir, S. A. (2026) · Toxicology Reports · doi:10.1016/j.toxrep.2026.102216 · Cited by 4
“In this situation, global data indicate a significant prevalence of 38 % and an annual incidence of 4613 cases per 100,000 people [40].”
Comparison of patients with HCC with and without MASLD after surgical resection
Ho, C.-J., Lei, H.-J., Ho, C.-T., Chau, G., Chou, S., Tan, E. C., Lee, P., Huang, Y., Yang, Y.-Y., Huo, T., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101768 · Cited by 2
“7,8 It is defined as steatotic liver disease (SLD) coexisting with at least one cardiometabolic risk factor (CMRF), including overweight or obesity, dysglycemia or type 2 diabetes mellitus, dyslipidemia, and hypertension.”
Prevalence of MASLD and fibrosis in Turkey: Results from a multicenter study of at-risk populations
Us, G. D., Innocenti, F., Koc, Ö. M., Yumuk, V., Öztürk, Z., & Koek, G. H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341214 · Cited by 2
Current status of research on the risk factors and pathogenesis of metabolic dysfunction-associated steatotic liver disease
Chen, D., Yan, L., Wu, T., Zhao, J., Xu, X., Xu, W., Zhang, H., & Xiao, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1819756 · Cited by 2
“Currently, obesity is widely recognized as one of the major causative factors of MASLD (14).”
Frequent fried food intake fuels incidence of metabolic associated fatty liver disease attributed to acrylamide-induced hepatic lipid disorders through arachidonic acid-PGE2-PPARα axis
Wan, X., Liu, X., Meng, D., Wang, A., Song, X., Huang, Y., Zhang, F., Lin, X., Yao, J., Zheng, Y., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.04.059 · Cited by 2
Waistline to thigh circumference ratio as a predictor of MAFLD: a health care worker study with 2-year follow-up
Hao, X., He, H., Tao, L., Zhao, W., & Wang, P. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03229-4 · Cited by 2
“The incidence of 46.13 new MAFLD cases per 1,000 person-years has been reported on a global scale [26].”
BackgroundInfluential
Herbal treatments for non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials
Rathnayake, D. W., Sooriyaarachchi, P., Niriella, M. A., Ediriweera, D. S., & Perera, J. A. (2024) · Advances in Integrative Medicine · doi:10.1016/j.aimed.2024.08.016 · Cited by 2
Insight into the therapeutic effects of artesunate in relieving metabolic‐associated steatohepatitis from transcriptomic and lipidomics analyses
Yang, J., Huang, L., Ren, T. Y., Zeng, J., Shi, Y. W., & Fan, J. (2024) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13311 · Cited by 2
One-hour post-load glucose is associated with biopsy-proven metabolic dysfunction-associated steatotic liver disease in obese individuals
Yuan, F., Fang, D., Xu, H., Nie, Y., Cai, W., & Gu, T. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101588 · Cited by 2
In Silico Analysis of Saroglitazar and Ferulic Acid Binding to Human Ketohexokinase: Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Tiwari, K., Kumar, B., Tiwari, A., Dhamija, P., Vardhan, G., Dehade, A., & Kumar, V. (2025) · Cureus · doi:10.7759/cureus.79437 · Cited by 2
“Recognizing MASLD as a significant non-communicable disease, the WHO is crucial for developing tailored policies to address its multifaceted impact on health, economics, and patient well-being, underscoring the urgent need for collective action [7,8].”
A plasma metabolome‐derived model predicts severe liver outcomes of nonalcoholic fatty liver disease in the UK Biobank
Xu, X., Li, J., Fu, Y., Li, J., Shen, W., Tan, X. W., Wang, N., Wang, B., & Lu, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16533 · Cited by 2
Construction of a community-based primary screening and hospital-based confirmatory screening pathway in pediatric nonalcoholic fatty liver disease
Yao, M., Xing, Y.-F., Liu, S.-H., Peng, Y., Yang, S.-H., Chen, J., Zhao, J., & Wang, H. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i28.108321 · Cited by 2
“When only the routine examination indices of community health centers were included, ten variables were selected (Supplementary Table 10), with no strong multicollinearity being observed among them (Supplementary Table 11).”
Las Cortes Españolas en el régimen de Franco: nacimiento, desarrollo y extinción de una Cámara Orgánica
Martínez, G., & Ángel, M. (2012) · Congreso de los Diputados eBooks · Cited by 2
Peroxisome proliferator-activated receptors gama ameliorates liver fibrosis in non-alcoholic fatty liver disease by inhibiting TGF-β/Smad signaling activation
Zhang, Q., Zhao, W., Sun, Z., Dong, X., Zhu, L., Zhang, Z., Chen, X., Hu, Y., Du, M., Li, J., et al. (2024) · Frigid Zone Medicine · doi:10.2478/fzm-2024-0002 · Cited by 1
Propylthiouracil Induced Rat Model Reflects Heterogeneity Observed in Clinically Non-Obese Subjects with Nonalcoholic Fatty Liver Disease
Jin, Y., Liu, Q., Wang, Y., Wang, B., An, J., Chen, Q., Wang, T., & Shang, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910764 · Cited by 1
“Its prevalence is estimated to be up to 30% and is continuously increasing [2,3].”
Background
Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in rats
Yang, H., Zhang, C., Kim, W., Shi, M., Kılıçlıoğlu, M., Bayram, C., Bolar, I., Tozlu, Ö. Ö., Baba, C., Yuksel, N., et al. (2024) · eLife · doi:10.7554/elife.98427.3 · Cited by 8
Association between HALP and all-cause and specific mortality in US adult with nonalcoholic fatty liver disease cirrhosis: a cohort study of National Health and Nutrition Examination Survey 2005–2018
Zhang, R., Weng, G., Wang, J., Lin, Y.-Y., Chen, Q., Ou, Y., & Yu, J. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002959 · Cited by 1
“The global prevalence of NAFLD is as high as approximately 30.05% [2].”
Influential
Impact of inhaled corticosteroids on metabolic dysfunction-associated steatotic liver disease risk in COPD patients
Sun, J., Lee, H. J., Lee, H. J., Park, T. Y., Heo, E. Y., Kim, D. K., & Lee, H. W. (2025) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2025.101171 · Cited by 1
Research progress on probiotics and prebiotics in the treatment of nonalcoholic fatty liver disease
Bai, F.-P., Tang, J., Liao, X., & Jiang, Z.-X. (2025) · journal of nutritional oncology · doi:10.1097/jn9.0000000000000050 · Cited by 1

Authors: Le, M. H., Le, D. M., Baez, T. C., Wu, Y., Ito, T., Lee, E. Y., Lee, K., Stave, C. D., Henry, L., Barnett, S. D., Cheung, R., & Nguyen, M. H.
Affiliations: University of Vermont (US)
Burrell College of Osteopathic Medicine (US)
Third Affiliated Hospital of Sun Yat-sen University (CN)
Nagoya University (JP)
Stanford Medicine (US)
Stanford University (US)
VA Palo Alto Health Care System (US)
Corresponding author: Nguyen, Mindie H.
ORCID: Le, Michael H.
Wu, Yuankai
Ito, Takanori
Lee, KeeSeok
Stave, Christopher D.
Henry, Linda
Barnett, Scott D.
Cheung, Ramsey
Nguyen, Mindie H.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2023-08
Volume: 79
Issue: 2
Pages: 287-295
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2023.03.040
OpenAlex: W4362719751
Cited by: 303
References: 51
Citations by year: 2026: 71 · 2025: 98 · 2024: 98 · 2023: 35
FWCI: 11.80
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: NAFLD incidence, global prevalence, ultrasonography, obesity, overweight, smoking, sex differences, China, South Korea, Japan, cohort studies, risk factors, study quality bias, study design bias, publication bias
MeSH terms: Adult, Female, Humans, Male, Obesity, Cohort Studies, Incidence, Overweight, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks